Overview

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer

Status:
Not yet recruiting

Trial end date:
2031-05-31

Target enrollment:

Participant gender:

Summary

This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Anastrozole
Exemestane
Fluzoparib
Letrozole
Tamoxifen
Toremifene